Elutia, Inc. · NASDAQ:ELUT
Elutia — Q3 2024 Earnings Presentation
12 slides from Elutia's earnings presentation, Nov 14, 2024
Slide 1: 3rd Quarter 2024 Financial Results Call
3rd Quarter 2024 Financial Results Call C. Randal Mills PhD Chief Executive Officer Matt Ferguson Chief Financial Officer November 14, 2024
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation of Elutia Inc. (“Elutia,” “we,” “us,” “our” or the “Company”) (together with any other statements or information that we may make or discuss in connection herewith) contains forward-looking statements. All statements other than statements of historical fa
Slide 3: Investment Summary
Investment Summary Commercial-stage company with two high-growth proprietary product platforms: CIEDs & Breast Reconstruction Neurostimulators We are pioneering the drug-eluting biomatrix (DEB) to solve complex surgical problems not addressed by current technology • FDA clearance of EluPro in June 2
Slide 4: Setting the stage for full commercial launch in 2025
Setting the stage for full commercial launch in 2025 June 2024: EluPro receives FDA clearance for use with cardiac implantable electronic devices (CEIDs) and neurostimulators Make It Implant It Grow It Publish It First lot of EluPro First EluPro Strengthening Peer reviewed data manufactured and Anti
Slide 5: Implant It: Energizing market interest
Implant It: Energizing market interest FIRST STRONG Commercial Use: Initial Adoption: • First patient implant of EluPro • EluPro is being utilized across all on a CIED device: September 5, 2024 major cardiac implantable electronic device (CIED) brands • First patient implant of EluPro on a neurostim
Slide 6: First EluPro implants
Congrats Dr. Paul Majad and team. First EluPro implant in Northampt Cooley Dickinson Medi implants his first EluPro. ile, TX, 10/31/2024 irst global EluPro implant. . Catanzaro and EP lab team,
Slide 7: Grow It: Strengthening our sales presence
Grow It: Strengthening our sales presence • Expanding our footprint with key additions in Southern California and the Northeast through a balanced blend of direct and independent reps • Hybrid model: 12 direct reps, 34 independent reps, 9 product consultants • Submitted to over 100 hospital VACs • 3
Slide 8: Publish It: Scientific support to bolster commercial launch
Publish It: Scientific support to bolster commercial launch Initiated Clinical Study: • Started a multi-center registry study • Designed to evaluate outcomes of patients receiving EluPro during CIED implantation • Data will support our EU efforts for CE mark Peer Reviewed Publications: • Data publis
Slide 9: Publish It: Compelling findings on antimicrobial activity
Publish It: Compelling findings on antimicrobial activity Preclinical Model of Bacterial Recovery S. aureus (MRSA) (+) 0% S. Epidermidis (+) 0% A. baumannii (-) 0% H. influenzae (-) 0% 0% 20% 40% 80% 100% % Bacterial Recovery Conclusion: EluPro achieved > 99.99% reduction (vs. control) in bacterial
Slide 10: Enthusiastic Reception
88% EPs using TYRX polled said they would switch some Enthusiastic Reception • Potential industry partners or all their envelopes to • Treating physicians • Hospital purchasing organizations A more complete solution for a $600M market 2021 Marketing Survey. Data on file. 11
Slide 11: Financial Update – Q3 2024 vs. Q3 2023
Financial Update – Q3 2024 vs. Q3 2023 • Net sales $5.9M vs $6.1M • BioEnvelope sales $2.3M vs. $2.6M • SimpliDerm sales $3.1M vs. $2.6M • GAAP gross margin 46% (approx. the same from prior year period) • Adjusted gross margin1 61% vs 60% • Operating expense $13.0M vs $10.2M • Loss from operations $
Slide 12: Questions?
Questions? Its GO time S) Medicine Humanized |